These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

37 related articles for article (PubMed ID: 8885123)

  • 21. Effect of CYP2B6*6 on Steady-State Serum Concentrations of Bupropion and Hydroxybupropion in Psychiatric Patients: A Study Based on Therapeutic Drug Monitoring Data.
    Høiseth G; Haslemo T; Uthus LH; Molden E
    Ther Drug Monit; 2015 Oct; 37(5):589-93. PubMed ID: 25565674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans.
    Steuer AE; Schmidhauser C; Tingelhoff EH; Schmid Y; Rickli A; Kraemer T; Liechti ME
    PLoS One; 2016; 11(3):e0150955. PubMed ID: 26967321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].
    Szewczuk-Bogusławska M; Grzesiak M; Beszłej JA; Kiejna A
    Psychiatr Pol; 2004; 38(6):1093-104. PubMed ID: 15779673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine.
    Owen JR; Nemeroff CB
    Depress Anxiety; 1998; 7 Suppl 1():24-32. PubMed ID: 9597349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antidepressant drugs in the elderly--role of the cytochrome P450 2D6.
    Vandel P
    World J Biol Psychiatry; 2003 Apr; 4(2):74-80. PubMed ID: 12692778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic and pharmacodynamic of bupropion: integrative overview of relevant clinical and forensic aspects.
    Costa R; Oliveira NG; Dinis-Oliveira RJ
    Drug Metab Rev; 2019 Aug; 51(3):293-313. PubMed ID: 31124380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bupropion plasma levels and CYP2D6 phenotype.
    Pollock BG; Sweet RA; Kirshner M; Reynolds CF
    Ther Drug Monit; 1996 Oct; 18(5):581-5. PubMed ID: 8885123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.
    Jefferson JW; Pradko JF; Muir KT
    Clin Ther; 2005 Nov; 27(11):1685-95. PubMed ID: 16368442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bupropion: pharmacology and therapeutic applications.
    Foley KF; DeSanty KP; Kast RE
    Expert Rev Neurother; 2006 Sep; 6(9):1249-65. PubMed ID: 17009913
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chirality and neuropsychiatric drugs: an update on stereoselective disposition and clinical pharmacokinetics of bupropion.
    Dash RP; Rais R; Srinivas NR
    Xenobiotica; 2018 Sep; 48(9):945-957. PubMed ID: 28876959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bupropion sustained release: side effect profile.
    Settle EC
    J Clin Psychiatry; 1998; 59 Suppl 4():32-6. PubMed ID: 9554319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psychotropic medications and cytochrome P450 2D6: pharmacokinetic considerations in the elderly.
    Shulman RW; Ozdemir V
    Can J Psychiatry; 1997 Jun; 42 Suppl 1():4S-9S. PubMed ID: 9220124
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.